Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions
Ali‐Ahmed, Fatima , Pieper, Karen S. , North, Rebecca, Ezekowitz, Michael D. , Fonarow, Gregg C. , Go, Alan S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Singer, Daniel E. , Piccini, Jonathan P. , O’Brien, Emily C. , North, Rebecca , Allen, Larry A. , Chan, Paul S. , Freeman, James V. , Gersh, Bernard J. , Naccarelli, Gerald V. , Pokorney, Sean D. , Steinberg, Benjamin A. , Peterson, Eric D.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | May 4, 2020 | Volume: 6 | Issue: 4 | Pages: 263-272

10.1093/ehjqcco/qcaa040 | PMID 32392287 Get It

Abstract Aims To determine the extent of shared decision-making (SDM), during selection of oral anticoagulant (OAC) and rhythm control treatments, in patients with newly diagnosed atrial fibrillation (AF). Methods and results We evaluated survey data from 1006 patients with new-onset AF enrolled at 56 US sites participating in the SATELLITE substudy of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT II). Patients completed surveys at enrolment and at 6-month follow-up. Patients were asked about who made their AF treatment decisions. Shared decision-making was classified as one that the patient felt was an autonomous decision or a shared decision with their healthcare provider (HCP). Approximately half of patients reported that their OAC treatment decisions were made entirely by their HCP. Compared with those reporting no SDM, patients reporting SDM for OAC were more often female (47.2% vs. 38.4%), while patients reporting SDM for rhythm control were more often male (62.2% vs. 57.6%). The most important factors cited by patients during decision-making for OAC were reducing stroke and bleeding risk, and their HCP’s recommendations. After adjustment, patients with self-reported understanding of OAC, and rhythm control options, had higher odds of having participated in SDM [odds ratio (OR) 2.54, confidence interval (CI): 1.75–3.68 and OR 2.36, CI: 1.50–3.71, both P ≤ 0.001, respectively]. Conclusion Shared decision-making is not widely implemented in contemporary AF practice. Patient understanding about available therapeutic options is associated with a more than a two-fold higher likelihood of SDM, and may be a potential target for future interventions.
When the Temporal Artery Biopsy is Negative
Ford, Erika, Ford, E G, Smith, Jonathan H.

Mayo Clinic

The Neurologist | May 2, 2020 | Volume: 25 | Issue: 3 | Pages: 70-72

10.1097/nrl.0000000000000262 | PMID 32358464 Get It

Introduction: Older adults presenting with a new or changed headache pattern in the setting of a diagnosis of polymyalgia rheumatica (PMR) are at risk for incident giant cell arteritis. However, the differential diagnosis of headache has not been evaluated in patients with a negative temporal artery biopsy (TAB). Headache has not been described as a symptom of PMR. Methods: After prospectively identifying an individual felt to have headache attributed to PMR, we performed a chart review to identify additional cases. As a secondary outcome, we summarized alternative headache diagnoses in patients with PMR, headache and a negative TAB. Results: A 75-year-old woman presented with a subacute history of radiating cervical pain in the setting of a 3 month history of lower back stiffness at rest and fatigue. Clinical examination was suggestive of a cervicogenic headache. Following treatment with low-dose corticosteroid for PMR, headaches, cervical mobility and systemic findings resolved with treatment of PMR with low-dose corticosteroid. In our cohort of 36 patients, we identified a single additional patient meeting our study criteria for headache attributed to PMR. Three additional patients met all but 1 diagnostic criterion. The retrospective case was a 73-year-old woman with a subacute history of both morning-predominant headaches and muscle stiffness, diagnosed with PMR. Headaches remitted with low-dose corticosteroid and relapsed with corticosteroid taper. Conclusions: Headache attributed to PMR is a steroid-responsive syndrome which should be considered in an older adult presenting with features of PMR, when the TAB is negative. Diagnostic criteria for headache attributed to PMR are proposed.
Quality Outcomes Database Spine Care Project 2012–2020: milestones achieved in a collaborative North American outcomes registry to advance value-based spine care and evolution to the American Spine Registry
Asher, Anthony L. , Knightly, John J. , Mummaneni, Praveen V. , Alvi, Mohammed Ali , McGirt, Matthew J., Yolcu, Yagiz U. , Chan, Andrew K. , Glassman, Steven D. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Haid, Regis W., Fu, Kai-Ming, Wang, Michael Y. , Park, Paul , Bisson, Erica F. , Bydon, Mohamad , Alvi, Mohammed Ali , Fu, Kai-Ming, Harbaugh, Robert E.

Mayo Clinic

Neurosurgical Focus | May 1, 2020 | Volume: 48 | Issue: 5 | Pages: E2

10.3171/2020.2.focus207 | PMID 32357320 Get It

The Quality Outcomes Database (QOD), formerly known as the National Neurosurgery Quality Outcomes Database (N 2 QOD), was established by the NeuroPoint Alliance (NPA) in collaboration with relevant national stakeholders and experts. The overarching goal of this project was to develop a centralized, nationally coordinated effort to allow individual surgeons and practice groups to collect, measure, and analyze practice patterns and neurosurgical outcomes. Specific objectives of this registry program were as follows: “1) to establish risk-adjusted national benchmarks for both the safety and effectiveness of neurosurgical procedures, 2) to allow practice groups and hospitals to analyze their individual morbidity and clinical outcomes in real time, 3) to generate both quality and efficiency data to support claims made to public and private payers and objectively demonstrate the value of care to other stakeholders, 4) to demonstrate the comparative effectiveness of neurosurgical and spine procedures, 5) to develop sophisticated ‘risk models’ to determine which subpopulations of patients are most likely to benefit from specific surgical interventions, and 6) to facilitate essential multicenter trials and other cooperative clinical studies.” The NPA has launched several neurosurgical specialty modules in the QOD program in the 7 years since its inception including lumbar spine, cervical spine, and spinal deformity and cerebrovascular and intracranial tumor. The QOD Spine modules, which are the primary subject of this paper, have evolved into the largest North American spine registries yet created and have resulted in unprecedented cooperative activities within our specialty and among affiliated spine care practitioners. Herein, the authors discuss the experience of QOD Spine programs to date, with a brief description of their inception, some of the key achievements and milestones, as well as the recent transition of the spine modules to the American Spine Registry (ASR), a collaboration between the American Association of Neurological Surgeons and the American Academy of Orthopaedic Surgeons (AAOS).
Correlation of return to work with patient satisfaction after surgery for lumbar spondylolisthesis: an analysis of the Quality Outcomes Database
DiGiorgio, Anthony M. , Mummaneni, Praveen V. , Park, Paul , Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Foley, Kevin T. , Glassman, Steven D. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Wang, Michael Y. , Fu, Kai-Ming, Asher, Anthony L. , Virk, Michael S. , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Haid, Regis W., Slotkin, Jonathan R., Alvi, Mohammed Ali , Guan, Jian

Mayo Clinic

Neurosurgical Focus | May 1, 2020 | Volume: 48 | Issue: 5 | Pages: E5

10.3171/2020.2.focus191022 | PMID 32357321 Get It

OBJECTIVE Return to work (RTW) and satisfaction are important outcome measures after surgery for degenerative spine disease. The authors queried the prospective Quality Outcomes Database (QOD) to determine if RTW correlated with patient satisfaction. METHODS The QOD was queried for patients undergoing surgery for degenerative lumbar spondylolisthesis. The primary outcome of interest was correlation between RTW and patient satisfaction, as measured by the North American Spine Society patient satisfaction index (NASS). Secondarily, data on satisfied patients were analyzed to see what patient factors correlated with RTW. RESULTS Of 608 total patients in the QOD spondylolisthesis data set, there were 292 patients for whom data were available on both satisfaction and RTW status. Of these, 249 (85.3%) were satisfied with surgery (NASS score 1–2), and 224 (76.7%) did RTW after surgery. Of the 68 patients who did not RTW after surgery, 49 (72.1%) were still satisfied with surgery. Of the 224 patients who did RTW, 24 (10.7%) were unsatisfied with surgery (NASS score 3–4). There were significantly more people who had an NASS score of 1 in the RTW group than in the non-RTW group (71.4% vs 42.6%, p < 0.05). Failure to RTW was associated with lower level of education, worse baseline back pain (measured with a numeric rating scale), and worse baseline disability (measured with the Oswestry Disability Index [ODI]). CONCLUSIONS There are a substantial number of patients who are satisfied with surgery even though they did not RTW. Patients who were satisfied with surgery and did not RTW typically had worse preoperative back pain and ODI and typically did not have a college education. While RTW remains an important measure after surgery, physicians should be mindful that patients who do not RTW may still be satisfied with their outcome.
Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers
Carter, Simon , Gutman, Talia , Logeman, Charlotte , Cattran, D C, Lightstone, Liz , Bagga, Arvind , Barbour, Sean J. , Barratt, Jonathan , Boletis, John , Caster, Dawn J. , Floege, Jürgen , Hogan, Jonathan J., Lafayette, Richard , Malvar, Ana , Scholes‐Robertson, Nicole , Trimarchi, Hernán, Zhang, Hong , Ažukaitis, Karolis , Viecelli, Andrea K. , Dunn, Louese, Harris, David C.H. , Johnson, David W. , Laboi, Paul, Ryan, Jessica , Ruiz, Lorena , Wang, Angela Yee‐Moon , Lee, Achilles Hoi Kan, Fung, Samuel , Tong, M.K.H. , Teixeira‐Pinto, Armando , Alexander, Stephen I. , Craig, Jonathan C. , Investigators, on behalf of the SONG-GD, Floege, Jürgen , Kitching, A Richard , Johnson, David W , Wang, Angela Yee-Moon , Wilkie, Martin , Carter, Simon A , Barratt, Jonathan , Scholes-Robertson, Nicole , Coppo, Rosanna , Fervenza, Fernando C. , Hladunewich, Michelle , Hogan, Jonathan J. , Kitching, A. Richard , Malvar, Ana , Radhakrishnan, Jai , Rovin, Brad H. , Trimarchi, Hernán , Cho, Yeoungjee , Kerr, Peter G. , Shen, Jenny I. , Tong, Allison , Investigators, on behalf of the SONG-GD

Mayo Clinic

Clinical Journal of the American Society of Nephrology | April 30, 2020 | Volume: 15 | Issue: 5 | Pages: 673-684

10.2215/cjn.13101019 | PMID 32354728 Get It

Background and objectives Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown. We aimed to identify and prioritize outcomes important to patients and caregivers and to describe reasons for their choices. Design, setting, participants, & measurements We purposively sampled adult patients with glomerular disease and their caregivers from Australia, Hong Kong, the United Kingdom, and the United States. Participants identified, discussed, and ranked outcomes in focus groups using the nominal group technique; a relative importance score (between zero and one) was calculated. Qualitative data were analyzed thematically. Results Across 16 focus groups, 134 participants (range, 19–85 years old; 51% women), including 101 patients and 33 caregivers, identified 58 outcomes. The ten highest-ranked outcomes were kidney function (importance score of 0.42), mortality (0.29), need for dialysis or transplant (0.22), life participation (0.18), fatigue (0.17), anxiety (0.13), family impact (0.12), infection and immunity (0.12), ability to work (0.11), and BP (0.11). Three themes explained the reasons for these rankings: constraining day-to-day experience, impaired agency and control over health, and threats to future health and family. Conclusions Patients with glomerular disease and their caregivers highly prioritize kidney health and survival, but they also prioritize life participation, fatigue, anxiety, and family impact.
Longitudinal neuroimaging biomarkers differ across Alzheimer’s disease phenotypes
Sintini, Irene , Graff‐Radford, Jonathan , Senjem, Matthew L. , Martin, Peter R. , Kantarci, Kejal , Petersen, Ronald C. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Senjem, Matthew L , Kantarci, Kejal , Schwarz, Christopher G. , Machulda, Mary M. , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Whitwell, Jennifer L.

Mayo Clinic

Brain | April 29, 2020 | Volume: 143 | Issue: 7 | Pages: 2281-2294

10.1093/brain/awaa155 | PMID 32572464 Get It

Abstract Alzheimer’s disease can present clinically with either the typical amnestic phenotype or with atypical phenotypes, such as logopenic progressive aphasia and posterior cortical atrophy. We have recently described longitudinal patterns of flortaucipir PET uptake and grey matter atrophy in the atypical phenotypes, demonstrating a longitudinal regional disconnect between flortaucipir accumulation and brain atrophy. However, it is unclear how these longitudinal patterns differ from typical Alzheimer’s disease, to what degree flortaucipir and atrophy mirror clinical phenotype in Alzheimer’s disease, and whether optimal longitudinal neuroimaging biomarkers would also differ across phenotypes. We aimed to address these unknowns using a cohort of 57 participants diagnosed with Alzheimer’s disease (18 with typical amnestic Alzheimer’s disease, 17 with posterior cortical atrophy and 22 with logopenic progressive aphasia) that had undergone baseline and 1-year follow-up MRI and flortaucipir PET. Typical Alzheimer’s disease participants were selected to be over 65 years old at baseline scan, while no age criterion was used for atypical Alzheimer’s disease participants. Region and voxel-level rates of tau accumulation and atrophy were assessed relative to 49 cognitively unimpaired individuals and among phenotypes. Principal component analysis was implemented to describe variability in baseline tau uptake and rates of accumulation and baseline grey matter volumes and rates of atrophy across phenotypes. The capability of the principal components to discriminate between phenotypes was assessed with logistic regression. The topography of longitudinal tau accumulation and atrophy differed across phenotypes, with key regions of tau accumulation in the frontal and temporal lobes for all phenotypes and key regions of atrophy in the occipitotemporal regions for posterior cortical atrophy, left temporal lobe for logopenic progressive aphasia and medial and lateral temporal lobe for typical Alzheimer’s disease. Principal component analysis identified patterns of variation in baseline and longitudinal measures of tau uptake and volume that were significantly different across phenotypes. Baseline tau uptake mapped better onto clinical phenotype than longitudinal tau and MRI measures. Our study suggests that optimal longitudinal neuroimaging biomarkers for future clinical treatment trials in Alzheimer’s disease are different for MRI and tau-PET and may differ across phenotypes, particularly for MRI. Baseline tau tracer retention showed the highest fidelity to clinical phenotype, supporting the important causal role of tau as a driver of clinical dysfunction in Alzheimer’s disease.
Predictors of the Best Outcomes Following Minimally Invasive Surgery for Grade 1 Degenerative Lumbar Spondylolisthesis
Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Haid, Regis W., Mummaneni, Praveen V. , Alvi, Mohammed A, Alvi, Mohammed Ali , Guan, Jian

Mayo Clinic

Neurosurgery | April 29, 2020 | Volume: 87 | Issue: 6 | Pages: 1130-1138

10.1093/neuros/nyaa206 | PMID 32497184 Get It

Abstract BACKGROUND The factors driving the best outcomes following minimally invasive surgery (MIS) for grade 1 degenerative lumbar spondylolisthesis are not clearly elucidated. OBJECTIVE To investigate the factors that drive the best 24-mo patient-reported outcomes (PRO) following MIS surgery for grade 1 degenerative lumbar spondylolisthesis. METHODS A total of 259 patients from the Quality Outcomes Database lumbar spondylolisthesis module underwent single-level surgery for degenerative grade 1 lumbar spondylolisthesis with MIS techniques (188 fusions, 72.6%). Twenty-four-month follow-up PROs were collected and included the Oswestry disability index (ODI) change (ie, 24-mo minus baseline value), numeric rating scale (NRS) back pain change, NRS leg pain change, EuroQoL-5D (EQ-5D) questionnaire change, and North American Spine Society (NASS) satisfaction questionnaire. Multivariable models were constructed to identify predictors of PRO change. RESULTS The mean age was 64.2 ± 11.5 yr and consisted of 148 (57.1%) women and 111 (42.9%) men. In multivariable analyses, employment was associated with superior postoperative ODI change (β-7.8; 95% CI [−12.9 to −2.6]; P = .003), NRS back pain change (β −1.2; 95% CI [−2.1 to −0.4]; P = .004), EQ-5D change (β 0.1; 95% CI [0.01-0.1]; P = .03), and NASS satisfaction (OR = 3.7; 95% CI [1.7-8.3]; P < .001). Increasing age was associated with superior NRS leg pain change (β −0.1; 95% CI [−0.1 to −0.01]; P = .03) and NASS satisfaction (OR = 1.05; 95% CI [1.01-1.09]; P = .02). Fusion surgeries were associated with superior ODI change (β −6.7; 95% CI [−12.7 to −0.7]; P = .03), NRS back pain change (β −1.1; 95% CI [−2.1 to −0.2]; P = .02), and NASS satisfaction (OR = 3.6; 95% CI [1.6-8.3]; P = .002). CONCLUSION Preoperative employment and surgeries, including a fusion, were predictors of superior outcomes across the domains of disease-specific disability, back pain, leg pain, quality of life, and patient satisfaction. Increasing age was predictive of superior outcomes for leg pain improvement and satisfaction.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Weller, Michael , Lee, Eudocia Q. , Barnholtz‐Sloan, Jill S. , Barthel, Floris P , Batchelor, Tracy T. , Chang, Susan M. , DeGroot, John, Hegi, Monika E. , Huang, Raymond Y. , Lassman, Andrew B. , Lim, Michael , Mellinghoff, Ingo K. , Minniti, Giuseppe , Nathanson, David A. , Platten, Michael , Preusser, Matthias , Roth, Patrick , Sanson, Marc , Schiff, David , Short, Susan , Taphoorn, Martin , Tonn, Joerg-Christian, Tsang, Jonathan , Verhaak, Roel G.W. , Deimling, Andreas von , Zadeh, Gelareh , Reardon, David A. , Aldape, Kenneth , Bent, Martin J. van den , Weller, Michael , Short, Susan C , van den Bent, Martin J , Barnholtz-Sloan, Jill S , Platten, Michael , Preusser, Matthias , Sanson, Marc , von Deimling, Andreas , Mellinghoff, Ingo K , Huang, Raymond , Roth, Patrick , Barthel, Floris P , Wen, Patrick Yung , Alexander, Brian M. , Bindra, Ranjit S. , Chiocca, E Antonio , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Horbinski, Craig , Rhun, Émilie Le , Mehta, Minesh P. , Tonn, Joerg-Christian , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | April 20, 2020 | Volume: 22 | Issue: 8 | Pages: 1073-1113

10.1093/neuonc/noaa106 | PMID 32328653 Get It

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.
Marango, Jotin, Sirulnik, Andres, Chesi, Marta , Shimoyama, Manabu, Leibovitch, Boris A. , Zhou, Ming , Martínez, Yolanda , Bergsagel, P. Leif , Licht, Jonathan D.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 358-358

10.1182/blood.v106.11.358.358 Get It

Abstract Over 40% of cases of multiple myeloma (MM) are associated with translocations of the immunoglobulin heavy (IgH) chain gene gene. The t(4;14) translocation, present in ca. 20% of myeloma cases, results in the overexpression of two potential oncogenes, MMSET and FGFR3, via juxtaposition of their endogenous promoters to regulatory elements of the IgH locus. The presence of t(4;14), and MMSET overexpression, is an adverse prognostic factor in MM irrespective of FGFR3 expression. MMSET contains several conserved motifs found in proteins involved in chromatin function (PWWP, HMG, PHD domains) and in the epigenetic control of transcription (SET domain). Accordingly, we found that the two main isoforms of the MMSET protein exhibit exclusive nuclear localization in both transfected fibroblasts and myeloma cells carrying t(4;14). Towards our goal of defining the ability of MMSET to affect gene regulation and contribute to the disease pathogenesis, we found that the SET domain of MMSET possesses in vitro methyltransferase activity specific for core histones H3 and H4. Using a computational approach and theoretical extrapolation from the solved NMR structure of vSET, we identified residues in the active site of MMSET essential for catalysis, whose mutation drastically reduces enzymatic activity. Reporter assays using Gal4 fusion constructs showed that both the amino terminus of MMSET, containing the PWWP and HMG domains, as well as the SET-containing carboxy terminus act as transcriptional repressors. MMSET interacts physically and functionally with a number of known co-repressor molecules, such as HDAC1, HDAC2, Sin3a, and SIRT1, but not HDAC4 or HDAC6. As such, MMSET co-expression enhances HDAC1 and HDAC2-mediated repression in transcriptional reporter assays, and MMSET repression is partially relieved by the addition of an HDAC inhibitor. A yeast two hybrid screen identified a number of other functional partners of MMSET, including ZNF331/RITA (Rearranged in Thyroid Adenoma), a KRAB domain/zinc finger protein previously implicated in malignancy. MMSET and ZNF331 co-localize in the nuclei of transfected fibroblasts, co-immunoprecipitate, and display cooperative repression in reporter assays. Collectively, these data support the idea that MMSET is a biologically active, bifunctional transcriptional mediator acting as a HMT enzyme in chromatin remodeling and as a complex adaptor in the recruitment of repressor species. Presently we are modeling the biological effects of MMSET through a conditional overexpression system in a B cell line. While low levels of MMSET are ubiquitiously expressed, induction of high levels of MMSET expression in the B cell line is associated with growth suppression and G1 arrest. While paradoxical for a presumed oncoprotein, such actions have been observed for other disease-associated proteins such as Runx1/MTG8. In contrast, a myeloma cell line harboring t(4;14) proliferates in the presence of high level MMSET expression. RNAi-mediated knockdown of MMSET in these cells induces apoptotic cell death. This suggests that MMSET may be critical for growth and survival of myeloma cells. Profiling of gene expression changes in these systems should link the transcriptional and biological activities of MMSET.